Viewing entries tagged
$CELG

Pillz (GILD)

February 7, 2017

Gilead Sciences (GILD) will report Q4 results after the close with a conference call to follow at 4:30pm ET. GILD is expected to report earnings at 4:01pm. Current Capital IQ consensus stands at EPS of $2.60 and Revenues of $7.175 bln.

Getting Cellular (CELG)

January 25, 2017

Celgene (CELG) will report Q4 results tomorrow before the market opens with a conference call to follow at 9am ET. CELG is expected to report Q4 results at 7:30am. Current Capital IQ consensus stands at EPS of $1.60 on Revenue of $3.02 bln

$GILD Earnings

November 1, 2016

Gilead Sciences is expected to report Q3 earnings today after the close with a conference call to follow at 4:30 pm ET the same day.

Capital IQ Consensus calls for EPS of $2.84 & a revenue decline of 12.5% to $7.44 bln, compared to EPS of $3.22 on revenue of $8.51 bln in the same quarter last year.

FY16 guidance

Co updated guidance for FY16 in their Q2 earnings release.
- Lowered net product sales to between $29.5-30.5 bln from $30-31 bln; reaffirmed adj gross margin between 88-90%.

Techs:

GILD has been in a slump throughout 2016 as it sits down -26% YTD near the $73-area. The path of least resistance remains to the downside as price flirts with 2-1/2 year lows & its down-trending 50-day simple moving avg near $77.

Options Activity

Based on GILD options, the current implied volatility stands at ~ 33%, which is 67% higher than historical volatility (over the past 30 days). Based on the GILD Weekly Nov04 $74 straddle, the options market is currently pricing in a move of ~5% in either direction by weekly expiration (Friday).

Peers include: AMGN, RHHBY, NVS, CELG, SHPG, REGN, BMRN, ALXN, BIIB

RESULTS:

Gilead Sciences misses by $0.09, reports revs in-line; reaffirms FY16 (Dec) revs in-line

Reports Q3 (Sep) earnings of $2.75 per share, $0.09 worse than the Capital IQ Consensus of $2.84.
- Antiviral product sales, which include primarily products in Gilead's HIV and liver disease areas, were $6.8 billion for the third quarter of 2016 compared to $7.7 billion for the same period in 2015.
  - HIV and other antiviral product sales were $3.5 billion compared to $2.9 billion for the same period in 2015.
  - HCV product sales, which consist of Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), Sovaldi (sofosbuvir 400 mg) and Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg), were $3.3 billion compared to $4.8 billion for the same period in 2015.
- Other product sales, which include Letairis (ambrisentan), Ranexa (ranolazine) and AmBisome (amphotericin B liposome for injection), were $564 million for the third quarter of 2016 compared to $509 million for the same period in 2015.
Co reaffirms guidance for FY16 (Dec), sees FY16 (Dec) revs of 29.5-30.5 vs. $30.38 bln Capital IQ Consensus Estimate.

GILD notes they have seen 'strong adoption' of TAF-based regimens where they received reimbursement

In the US, of the nearly 840k people on antiretroviral therapy, 80% receive a Gilead regiment

Anticipated Milestones:

Achieve 48-week endpoint in Phase 3 studies in treatment-naïve and switch patients
Complete Phase 1 study in HIV cure.
Complete enrollment of Phase 2 study in HCM
Complete Phase 3 study in LQT-3 syndrome
Complete Phase 2 study in HCM
Complete Phase 2 study in ebola virus disease

Geting Cellular ($CELG Earnings Preview)

July 27, 2016

Capital IQ Consensus calls for 2Q16 EPS of $1.39 & revenue growth of 18.9%, compared to 2Q15 EPS of $1.23 on revenue of $2.28 bln.

At a Crossroad 4/25 Weekly Setups and Preview

April 25, 2016

With poor earnings from $V $SBUX $GOOGL/$GOOG and $MSFT, the market had every reason to let the bottom fall out and collapse on Friday. Though we started lower, we ended the day slightly in the positive for the S&P 500. The Q's took it early but finished moderately lower. The A/D line continues to broaden and the market continues to catch a bid. Unlike the last couple of years, the broader market participation has been stellar and it seems every couple of weeks there is a rotation into a new group. The main focal point on Friday was the IWM which ended firmly in the green. Until this musical chairs of money rotation ends, there is no reason to believe that the bears have any semblance of control. There are two levels of support currently where dip buyers step in. Near the 9 and the 20MA's. It's important that the momentum continues and the market continues to churn higher as we've broken our downtrends (for now).